Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response

Pharmacotherapy

Volumn 17, Issue 6, 1997, Pages 1305-1310

  Sowinski, Kevin M ^a,c   Burlew, Brad S ^b  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYPROPRANOLOL; CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DRUG METABOLITE; GLUCURONIDE; OXYGENASE; PROPRANOLOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; TREADMILL EXERCISE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; HALF-LIFE; HEART RATE; HUMANS; HYDROXYLATION; MALE; PHENOTYPE; PROPRANOLOL;

EID: 0030689757     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Walle T, Walle UK, Olanoff LS. Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos 1985;13:204-9.
2. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated by CYP1A2. Br J Clin Pharmacol 1995;39:421-31.
3. Masubuchi Y, Hosokawa S, Horie T, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994;22: 909-15.
4. Ward SA, Walle T, Walle UK, Wilkinson GR, Brance RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
5. Shaheen O, Biollaz J, Koshakji RP, Wilkinson GR, Wood AJJ. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. Clin Pharmacol Ther 1989;45:439-43.
6. Marathe PH, Shen DD, Nelson WL. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition. Drug Metab Dispos 1994;22:237-47.
7. Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF. The relationship between debrisoquine phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 1984;17:679-85.
8. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta-blockade. Clin Pharmacol Ther 1984;36:51-6.
9. Fitzgerald JD, O'Donnell SR. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol 1971;43:222-35.
10. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin poor metabolizer phenotype in american black versus white subjects. Clin Pharmacol Ther 1991:50:308-13.
11. Zhou HH, Anthony LB, Roden DM, Wood AJJ. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 1990;47:686-93.
12. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989:45:568-73.
13. Relling MV, Ayers D, Heideman RL. Mephenytoin phenotyping: lack of hematologie effect and timing of urine collections. Pharmacogenetics 1991;1:42-9.
14. Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA. Racial differences in propranolol enantiomer kinetics following simultaneous IV and oral administration. Br J Clin Pharmacol 1996:42:339-46.
15. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
16. Bichara N, Ching MS, Blake CL, Ghabrial H, Smallwood RA. Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6. Studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions. Drug Metab Dispos 1996;43:112-18.